peptidechats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Sermorelin

Also known as: GHRH(1-29)NH2, hGRF(1-29)NH2, GRF 1-29, Geref, hGHRH(1-29)-NH2, SERM, CJC-1293 enantiomer

Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue

Ask about Sermorelin in chat →

What it is

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal active fragment of endogenous hypothalamic growth hormone-releasing hormone (GHRH). It binds to and activates the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, stimulating the secretion of endogenous growth hormone (GH), which in turn elevates circulating insulin-like growth factor-1 (IGF-1) levels. The peptide's plasma half-life is approximately 10–20 minutes in humans, limited primarily by renal ultrafiltration and enzymatic N-terminal degradation. Beyond pituitary actions, the GHRH receptor and its splice variants are expressed in multiple extrapituitary tissues including cancer cell lines, cardiac myocytes, retinal cells, corneal endothelium, and immune cells; activation or antagonism of this receptor modulates proliferation, apoptosis, inflammation, and redox signalling through pathways including cAMP/PKA, MAPK/ERK, JAK/STAT3, NF-κB, and HIF-1α. In the context of growth hormone secretagogue use, sermorelin has been used in combination with GHRPs (GHRP-2, GHRP-6) to raise IGF-1 levels, with GHRP-6 itself requiring endogenous GHRH signalling for maximal GH stimulation.

Class: Growth Hormone-Releasing Hormone (GHRH) analogue; growth hormone secretagogue

What it's studied for

  • Growth hormone secretagogue — raising serum IGF-1 in hypogonadal men on testosterone therapy Human observational
    • Retrospective review of 14 hypogonadal men prescribed 100 mcg each of GHRP-6, GHRP-2, and sermorelin (SERM) three times daily. Mean posttreatment IGF-1 rose from 159.5 to 239.0 ng/mL (p<0.0001) over a mean 134 days of treatment. Co-administration of aromatase inhibitors or tamoxifen attenuated IGF-1 increases. PMID 28830317 Sigalos JT et al. Am J Mens Health. 2017
  • Diagnostic / physiological probe for GH secretion assessment Human RCT
    • GHRH (100 mg, i.v.) with and without pyridostigmine was used to study GH dynamics in tall vs. short postpubertal men. No significant difference in GH response to GHRH was found between groups, and quantitative GH secretion did not appear to be an important determinant of final adult height in healthy individuals. PMID 10594520 Trainer PJ et al. Clin Endocrinol. 1999
    • In healthy men, a specific GHRH antagonist (400 mcg/kg i.v.) blocked most of the GH response to GHRP-6 (1 mcg/kg i.v.), demonstrating that endogenous GHRH is necessary for most GH release elicited by GHRP-6. PMID 9543138 Pandya N et al. J Clin Endocrinol Metab. 1998
  • Sports / athletic performance enhancement (off-label, unapproved use) Human observational
    • Narrative review documenting sermorelin as one of the most commonly encountered GHRH analogues in online self-administration protocols for GH-IGF-1 axis modulation. Notes absence of regulatory approval for physique/performance indications and uncertainty about product composition, dosing, and stacking in unregulated su PMID 42395176 Dominikowski A et al. Front Endocrinol. 2026
    • Review covering sermorelin as an unapproved peptide marketed to sports medicine patients. Notes favorable tissue repair and metabolic outcomes in animal models but scarcity of rigorous human safety data and potential for serious patient harm. PMID 41966639 Mendias CL & Awan TM. Sports Med. 2026
    • Critical review classifying sermorelin as a GHRH analogue promoted for muscle growth, fat metabolism, and recovery. Notes most clinical evidence is from controlled therapeutic dosing, not supraphysiological or combined protocols used in bodybuilding. Highlights potential risks: cardiovascular strain, insulin resistance PMID 41880199 Coutinho LFD et al. J Sports Med Phys Fitness. 2026
  • Musculoskeletal injury recovery / orthopaedic adjunct (proposed, largely preclinical) Animal studies only
    • Review noting that growth hormone secretagogues including sermorelin activate IGF-1 signalling and satellite cell repair. Concludes preclinical studies are promising but there is a current lack of clinical trials for orthopaedic applications. PMID 41490200 Rahman OF et al. J Am Acad Orthop Surg Glob Res Rev. 2026
  • Adult-onset growth hormone insufficiency management Human observational
    • Editorial discussing sermorelin as an approach to management of adult-onset growth hormone insufficiency (no abstract text provided; limited extractable data). PMID 18046908 Walker RF. Clin Interv Aging. 2006
  • Cardioprotection / heart failure (preclinical — GHRH receptor agonist pathway, studied with synthetic GHRH agonists, not sermorelin itself) Animal studies only
    • Sermorelin is listed as a named GHRH receptor agonist in the MeSH of this study investigating the GHRHR-HIF-1α axis in HFpEF mouse models and human iPSC-derived cardiomyocytes. The experimental agent used was MR-356, not sermorelin. Study demonstrates the GHRHR-HIF-1α axis is required for beneficial cardiac effects of PMID 42465868 Kanashiro-Takeuchi RM et al. Am J Physiol Heart Circ Physiol. 2026
    • GHRH agonists (JI-38, MR-356, MR-409) reduced MI size, increased cardiac c-kit+ cells, mitotic divisions, and vascular density in infarcted rats. Sermorelin is listed in MeSH context as a GHRH reference compound; the active agents studied were synthetic agonists, not sermorelin itself. PMID 25797248 Kanashiro-Takeuchi RM et al. Oncotarget. 2015
  • Diabetic retinopathy protection (preclinical, GHRH agonist pathway) Animal studies only
    • Streptozotocin-diabetic rats treated with GHRH agonist MR-409 (15 µg/kg) showed retinal neuroprotection, antioxidant and anti-inflammatory effects, and reduced vascular permeability. Sermorelin appears in MeSH as a GHRH reference; the active agent studied was MR-409. PMID 29180438 Thounaojam MC et al. PNAS. 2017
  • Type 1 diabetes / beta-cell protection (preclinical, GHRH agonist pathway) Animal studies only
    • GHRH agonist MR-409 protected beta-cells from streptozotocin-induced T1D in mice via cAMP/PKA/CREB/IRS2 signalling. Sermorelin appears in MeSH as a GHRH reference compound; the active agent studied was MR-409. PMID 37307472 Louzada RA et al. PNAS. 2023
  • Doping control detection target (anti-doping / forensic analytical context) Human observational
    • Nano-LC-Q/Orbitrap MS method validated to WADA requirements for detection of sermorelin/CJC-1293, tesamorelin, and CJC-1295 in urine; achieved LODs ≤0.5 ng/mL and LOIs 0.5–0.75 ng/mL. PMID 41138283 Uçaktürk E & Nemutlu E. J Pharm Biomed Anal. 2026
    • LC-MS/MS method developed for detection of sermorelin and metabolites in urine; LOD generally ≤1 ng/mL. Nineteen in vitro metabolites of GHRH analogues including sermorelin were identified and used as reference materials. PMID 34665524 Memdouh S et al. Drug Test Anal. 2021
    • Immunoaffinity purification with nano-UHPLC-HRMS method detected sermorelin (Geref), CJC-1293, CJC-1295, and tesamorelin in human plasma; LLOQ <50 pg/mL. A sermorelin metabolite (GHRH3-29) was detected in human plasma after s.c. injection to a healthy male volunteer. PMID 26879649 Knoop A et al. Anal Bioanal Chem. 2016

Community-reported dosing

RouteDoseFrequency / DurationPopulation / contextSource tier
Not explicitly stated in abstract (prescribed combination therapy)100 mcg of sermorelin (SERM) three times daily (combined with 100 mcg GHRP-6 and 100 mcg GHRP-2 three times daily)Mean 134 days (range not fully specified)humanResearch PMID 28830317
intravenous100 mg GHRH intravenously (diagnostic bolus)Single administrationhumanResearch PMID 10594520
intravenous1 mcg/kg GHRP-6 i.v. bolus (with or without 400 mcg/kg i.v. GHRH antagonist); sermorelin used as GHRH referenceSingle administrationhumanResearch PMID 9543138
subcutaneousDose not specified (pharmacokinetic/metabolite study after s.c. injection to one healthy male volunteer)Single administration; samples collected at 2, 4, 8 h post-dosehumanResearch PMID 26879649
intravenous, subcutaneousNot specified for sermorelin alone; PEGylated GRF conjugates tested i.v. and s.c. in rats and pigsNot specifiedanimalResearch PMID 14499707
subcutaneous injection200-300 mcgdaily, before bedadults 30+ using for anti-aging / longevity, GH optimization[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection300 mcgdaily, before bedmen 40+ on TRT seeking GH axis support without exogenous HGH[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200 mcgdaily, before bedbeginners / newcomers to GH secretagogues[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection500 mcgdaily, before bedexperienced biohackers seeking stronger GH pulse amplitude[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection100 mcgdaily, before bedolder adults (60+) or those with pituitary sensitivity concerns[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200-300 mcgdaily, before bedathletes and fitness-focused adults targeting sleep quality and recovery[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200 mcgdaily, before bedhealthy adults using Sermorelin + GHRP-2 stack[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200 mcgdaily, before bedhealthy adults using Sermorelin + GHRP-6 stack[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection200 mcgdaily, before bedbody recomposition users combining Sermorelin with Ipamorelin[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection300 mcg5 days on / 2 days off (weekdays)biohackers preferring cycling protocols to limit pituitary desensitization[S] Claude Sonnet 4.6 — synthesized from aggregate training data
subcutaneous injection500 mcgtwice daily (morning fasted + pre-bed)advanced biohackers seeking maximal GH output, often stacked with a GHRP[S] Claude Sonnet 4.6 — synthesized from aggregate training data

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

  • Long-term self-administration of sermorelin/GHRP-6 combination (approximately 20 years) associated in a single case report with symptomatic anterior cervical osteophyte formation and dysphagia in a 62-year-old male; causality unproven but hypothesis raised regarding chronic GH axis stimulation contributing to osteophyte growth in setting of prior cervical trauma PMID 42456877
  • Off-label GH-axis peptide use (including sermorelin) associated with reported adverse effects spanning endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions PMID 42395176
  • Potential cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability reported in association with peptide use (including GHRH analogues such as sermorelin) in bodybuilding contexts PMID 41880199
  • Products sourced from unregulated gray markets may be mislabeled or contaminated, posing direct patient safety risks; sermorelin has been identified among seized falsified biopharmaceutical injectables in Europe PMID 36456392
  • Rigorous human safety data for sermorelin use in sports/performance contexts are scarce; potential for serious harm acknowledged PMID 41966639
  • Inhibition of estrogen production or estrogen receptor blockade (co-administration of aromatase inhibitors or tamoxifen) during GHRP/sermorelin therapy resulted in smaller increases in IGF-1 levels, suggesting hormonal interactions that may affect therapeutic outcomes PMID 28830317

Contraindications

  • No absolute contraindications are explicitly stated in the reviewed abstracts. The reviewed literature does not provide formal contraindication data for sermorelin in human therapeutic use. PMID 41966639

Frequently asked

What does sermorelin do and how does it work?

Sermorelin is a synthetic 29-amino-acid peptide that mimics the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland, stimulating the release of endogenous growth hormone, which in turn raises IGF-1 levels. Its plasma half-life in humans is approximately 10–20 minutes due to rapid enzymatic and renal clearance.

What dose of sermorelin should I take?

I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: one retrospective study in hypogonadal men used 100 mcg of sermorelin combined with 100 mcg GHRP-6 and 100 mcg GHRP-2 three times daily. In diagnostic settings, GHRH has been administered as a single 100 mg i.v. bolus. These doses were used in specific research contexts and should not be extrapolated to individual self-administration.

Is sermorelin legal or banned?

GHRH and its synthetic analogues, including sermorelin, are prohibited by the World Anti-Doping Agency (WADA) in competitive sport. Multiple validated detection methods exist for sermorelin in urine and plasma to enforce this prohibition. Its prescription regulatory status in specific countries is not explicitly stated in the reviewed literature — please consult a licensed healthcare provider or the relevant regulatory authority for your jurisdiction.

Can sermorelin be used for muscle building or athletic performance?

Sermorelin is used off-label and without regulatory approval for physique and performance-related purposes. Reviewed literature notes its use in these contexts but concludes that clinical evidence is limited, most published studies examine therapeutic applications under controlled dosing, and potential risks include cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability. Sermorelin is prohibited by WADA in competitive sport. Products obtained outside licensed channels may be mislabeled or contaminated.

What are the side effects or safety risks of sermorelin?

Based on reviewed literature, reported concerns associated with sermorelin and related GH-axis peptides include: endocrine/metabolic disturbances (prolactin and cortisol elevations, appetite changes, dysglycaemia), fluid retention, myalgia/arthralgia, and injection-site reactions. One case report associates approximately 20 years of sermorelin/GHRP-6 combination use with cervical osteophyte formation and dysphagia, though causality was not established. Unregulated supply carries contamination and mislabeling risks. Rigorous human safety data for off-label performance use are scarce.

Can I combine sermorelin with other peptides like ipamorelin, CJC-1295, or GHRP-6?

I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: one retrospective study used a combination of sermorelin with GHRP-6 and GHRP-2 (each 100 mcg three times daily) and observed IGF-1 increases. A mechanistic study showed GHRP-6 requires endogenous GHRH signalling for maximal GH stimulation, which is the pharmacological rationale for combinations. Risks associated with combined peptide protocols, including unregulated stacking, are not well characterised in the literature.

Where can I buy sermorelin?

I don't recommend vendors or sources. Please consult a licensed provider.

Will sermorelin show up on a drug test?

Yes. Multiple validated analytical methods have been developed specifically to detect sermorelin (and its metabolites) in urine and plasma for WADA anti-doping purposes. Achieved limits of detection in urine are ≤0.5–1 ng/mL. In a pharmacokinetic study, a sermorelin metabolite (GHRH3-29) was detected in human plasma at 4–8 hours after a single subcutaneous dose.

Is sermorelin safe for long-term use?

Long-term safety data for sermorelin in healthy adults are not established in the reviewed literature. One case report described a 62-year-old man with approximately 20 years of cyclical sermorelin/GHRP-6 combination use who developed symptomatic cervical osteophyte formation, though causality was not proven. Reviewed literature consistently notes that rigorous human safety data are scarce and that long-term risks remain poorly defined. Please speak with a licensed healthcare provider.

Does sermorelin help with fat loss?

I don't have reliable study data on sermorelin specifically for fat loss in the reviewed abstracts. One retrospective study in hypogonadal men prescribed sermorelin combined with GHRPs noted that participants were seeking lean body mass and fat loss, and IGF-1 levels increased significantly, but body composition outcomes were not reported. I won't guess — please consult a licensed provider or peer-reviewed literature directly.

References

  1. [1] PMID 28830317 — Retrospective review of 14 hypogonadal men prescribed 100 mcg each of GHRP-6, GHRP-2, and sermorelin (SERM) three times daily. Mean posttreatment IGF-1 rose fro
  2. [2] PMID 10594520 — GHRH (100 mg, i.v.) with and without pyridostigmine was used to study GH dynamics in tall vs. short postpubertal men. No significant difference in GH response t
  3. [3] PMID 9543138 — In healthy men, a specific GHRH antagonist (400 mcg/kg i.v.) blocked most of the GH response to GHRP-6 (1 mcg/kg i.v.), demonstrating that endogenous GHRH is ne
  4. [4] PMID 42395176 — Narrative review documenting sermorelin as one of the most commonly encountered GHRH analogues in online self-administration protocols for GH-IGF-1 axis modulat
  5. [5] PMID 41966639 — Review covering sermorelin as an unapproved peptide marketed to sports medicine patients. Notes favorable tissue repair and metabolic outcomes in animal models
  6. [6] PMID 41880199 — Critical review classifying sermorelin as a GHRH analogue promoted for muscle growth, fat metabolism, and recovery. Notes most clinical evidence is from control
  7. [7] PMID 41490200 — Review noting that growth hormone secretagogues including sermorelin activate IGF-1 signalling and satellite cell repair. Concludes preclinical studies are prom
  8. [8] PMID 18046908 — Editorial discussing sermorelin as an approach to management of adult-onset growth hormone insufficiency (no abstract text provided; limited extractable data).
  9. [9] PMID 42465868 — Sermorelin is listed as a named GHRH receptor agonist in the MeSH of this study investigating the GHRHR-HIF-1α axis in HFpEF mouse models and human iPSC-derived
  10. [10] PMID 25797248 — GHRH agonists (JI-38, MR-356, MR-409) reduced MI size, increased cardiac c-kit+ cells, mitotic divisions, and vascular density in infarcted rats. Sermorelin is
  11. [11] PMID 29180438 — Streptozotocin-diabetic rats treated with GHRH agonist MR-409 (15 µg/kg) showed retinal neuroprotection, antioxidant and anti-inflammatory effects, and reduced
  12. [12] PMID 37307472 — GHRH agonist MR-409 protected beta-cells from streptozotocin-induced T1D in mice via cAMP/PKA/CREB/IRS2 signalling. Sermorelin appears in MeSH as a GHRH referen
  13. [13] PMID 41138283 — Nano-LC-Q/Orbitrap MS method validated to WADA requirements for detection of sermorelin/CJC-1293, tesamorelin, and CJC-1295 in urine; achieved LODs ≤0.5 ng/mL a
  14. [14] PMID 34665524 — LC-MS/MS method developed for detection of sermorelin and metabolites in urine; LOD generally ≤1 ng/mL. Nineteen in vitro metabolites of GHRH analogues includin
  15. [15] PMID 26879649 — Immunoaffinity purification with nano-UHPLC-HRMS method detected sermorelin (Geref), CJC-1293, CJC-1295, and tesamorelin in human plasma; LLOQ <50 pg/mL. A serm
  16. [16] PMID 14499707 — Not specified for sermorelin alone; PEGylated GRF conjugates tested i.v. and s.c. in rats and pigs intravenous, subcutaneous (animal)
  17. [17] PMID 42456877 — Long-term self-administration of sermorelin/GHRP-6 combination (approximately 20 years) associated in a single case report with symptomatic anterior cervical os
  18. [18] PMID 36456392 — Products sourced from unregulated gray markets may be mislabeled or contaminated, posing direct patient safety risks; sermorelin has been identified among seize
  19. [19] PMID 54499707 — in-prose reference
  20. [20] PMID 33282817 — in-prose reference
Dial in your dose in chat →

Related peptides

SS-31Mitochondria-targeted synthetic tetrapeptide antioxidantSemaxSynthetic nootropic/neuroprotective heptapeptide; melanocortin-related peptide; ACTH analo…SurvodutideDual glucagon receptor (GCGR) / glucagon-like peptide-1 receptor (GLP-1R) agonist; investi…